by Admin | Dec 22, 2020 | Portfolio News
Today Eccogene announces that it has completed a new series financing of more than 100 million RMB, co-led by Delos Capital and Oriza Seed, with participation from new investors HuaGai Capital, Tsing Song Capital and existing investor Sinopharm Capital. The raised...
by Admin | Dec 21, 2020 | Portfolio News
December 21, 2020 02:00 ET | Source: Allecra Therapeutics GmbH; Shanghai Haini Pharmaceutical Co., Ltd. Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is...
by Admin | Dec 4, 2020 | Portfolio News
Clover Biopharmaceuticals is set to start a phase 2/3 clinical trial of a COVID-19 vaccine featuring an adjuvant from GlaxoSmithKline. The Chinese vaccine developer committed to starting the study later this month after reviewing data on 150 participants in a phase 1...
by Admin | Dec 1, 2020 | Portfolio News
Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen for Hepatitis B (“HBV”) ATLANTA, Dec. 01, 2020 (GLOBE NEWSWIRE) —...
by Admin | Nov 12, 2020 | Portfolio News
Oncolytic viruses hold promise as cancer treatments due to their cancer-killing prowess and ability to be combined with other therapies. But few drugs derived from oncolytic viruses have made it to the market. Arizona State University spinout OncoMyx Therapeutics is...
by Admin | Nov 6, 2020 | Portfolio News
PHOENIX, November 6, 2020 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company’s board of directors. Dr. Baum is currently president and chief...
